RNA Modification in Metabolism
10.1002/mco2.70135 · doi-reference
Epitranscriptomics in Hematopoiesis and Hematologic Malignancies
10.1158/2643-3249.bcd-20-0032 · doi-reference
Molecular Features, Biological Behaviors and Clinical Implications of M 5C RNA Methylation Modification Regulators in Gastrointestinal Cancers
10.1080/15384047.2023.2223382 · doi-reference
Biomarkers related to m⁶A and succinic acid metabolism in papillary thyroid carcinoma
10.1186/s12920-024-01975-8 · doi-reference
Novel insights into the N 6-methyladenosine modification on circRNA in cancer
10.5772/intechopen.1005693 · doi-reference
The interplay between m⁶A modification and non-coding RNA in cancer stemness modulation: mechanisms, signaling pathways, and clinical implications
10.7150/ijbs.60641 · doi-reference
N(6)-methyladenosine as a biological and clinical determinant in colorectal cancer: progression and future direction
10.7150/thno.52366 · doi-reference
The epigenetic basis of hepatocellular carcinoma - mechanisms and potential directions for biomarkers and therapeutics
10.1038/s41416-025-02969-8 · doi-reference
On the road to colorectal cancer development: crosstalk between the gut microbiota, metabolic reprogramming, and epigenetic modifications
10.1093/carcin/bgad058 · doi-reference
Targeting epigenetic regulators as a promising avenue to overcome cancer therapy resistance
10.1038/s41392-025-02266-z · doi-reference
Bone Marrow Mesenchymal Stem Cells Induce Metabolic Plasticity in Estrogen Receptor-Positive Breast Cancer
10.1158/1541-7786.mcr-22-0451 · doi-reference
Advances in RNA Epigenetic Modifications in Hepatocellular Carcinoma and Potential Targeted Intervention Strategies
10.3389/fcell.2021.777007 · doi-reference
Cellular adaptation to cancer therapy along a resistance continuum
10.1038/s41586-024-07690-9 · doi-reference
Persister cell plasticity in tumour drug resistance
10.1016/j.semcdb.2023.11.003 · doi-reference
The Transcriptional and Epigenetic Landscape of Cancer Cell Lineage Plasticity
10.1158/2159-8290.cd-23-0225 · doi-reference
Manipulation of Mitochondrial Plasticity Changes the Metabolic Competition Between "Foe" and "Friend" During Tumor Malignant Transformation
10.3389/fonc.2020.01692 · doi-reference
Mitochondrial metabolic reprogramming in colorectal cancer: mechanisms of resistance and future clinical interventions
10.1038/s41420-025-02670-y · doi-reference
Glioblastomas: Hijacking Metabolism to Build a Flexible Shield for Therapy Resistance
10.1089/ars.2022.0088 · doi-reference
Rewiring of mitochondrial metabolism in therapy-resistant cancers: permanent and plastic adaptations
10.3389/fcell.2023.1254313 · doi-reference
Metabolic Plasticity and Cancer Stem Cell Metabolism: Exploring the Glycolysis-OXPHOS Switch as a Mechanism for Resistance and Tumorigenesis
10.1007/s12015-025-10956-y · doi-reference
Epigenetics and metabolism at the crossroads of stress-induced plasticity, stemness and therapeutic resistance in cancer
10.7150/thno.42523 · doi-reference
Metabolic adaptations in cancer stem cells: A key to therapy resistance
10.1016/j.bbadis.2024.167164 · doi-reference
Metabolic regulation of myeloid-derived suppressor cells in tumor immune microenvironment: targets and therapeutic strategies
10.7150/thno.105276 · doi-reference
Targeting cholesterol metabolism in tumor and its immune microenvironment: opportunities and challenges
10.1016/j.bbcan.2025.189422 · doi-reference
Harnessing Metabolic Reprogramming to Improve Cancer Immunotherapy
10.3390/ijms221910268 · doi-reference
Metabolic rewiring and communication in cancer immunity
10.1016/j.chembiol.2024.02.001 · doi-reference
Metabolic challengers selecting tumor-persistent cells
10.1016/j.tem.2023.11.005 · doi-reference
Metabolic Plasticity in Melanoma Progression and Response to Oncogene Targeted Therapies
10.3390/cancers13225810 · doi-reference
Macrophage-targeting combination therapy enhances T-DXd-induced tumor regression
10.1016/j.intimp.2025.114378 · doi-reference
Copper-doped layered double hydroxides co-deliver proteins/drugs for cascaded chemodynamic/immunotherapy via dual regulation of tumor metabolism
10.1016/j.actbio.2025.02.008 · doi-reference
Tumor microenvironment responsive polypeptide-based supramolecular nanoprodrugs for combination therapy
10.1016/j.actbio.2022.04.027 · doi-reference
Combined PARP Inhibition and Immune Checkpoint Therapy in Solid Tumors
10.3390/cancers12061502 · doi-reference
Metabolic interventions combined with CTLA-4 and PD-1/PD-L1 blockade for the treatment of tumors: mechanisms and strategies
10.1007/s11684-023-1025-7 · doi-reference
Glutamine's double-edged sword: fueling tumor growth and offering therapeutic hope
10.3389/fimmu.2025.1578940 · doi-reference
The Advances in Epigenetics for Cancer Radiotherapy
10.3390/ijms23105654 · doi-reference
LRPPRC promotes glycolysis by stabilising LDHA mRNA and its knockdown plus glutamine inhibitor induces synthetic lethality via m(6) A modification in triple-negative breast cancer
10.1002/ctm2.1583 · doi-reference
The regulation of N⁶-methyladenosine modification in PD-L1-induced anti-tumor immunity
10.1111/imcb.12620 · doi-reference
Recent Advances of IDH1 Mutant Inhibitor in Cancer Therapy
10.3389/fphar.2022.982424 · doi-reference
Targeting Oncometabolism to Maximize Immunotherapy in Malignant Brain Tumors
10.1038/s41388-022-02312-y · doi-reference
The Curious Case of IDH Mutant Acute Myeloid Leukaemia: Biochemistry and Therapeutic Approaches
10.1042/bst20230017 · doi-reference
